Experimental MS therapy outperforms approved treatment in trials

Experimental MS therapy remibrutinib reduced relapse rates and brain lesion activity more than Aubagio in two Phase 3 trials.

Experimental MS therapy remibrutinib reduced relapse rates and brain lesion activity more than Aubagio in two Phase 3 trials.